Ranbaxy's generic Lipitor buoys Daiichi Sankyo against olmesartan weakness
This article was originally published in Scrip
Daiichi Sankyo's branded-plus-generics "hybrid" business model finally appears to be paying concrete dividends, with Ranbaxy's surging sales of generic atorvastatin offsetting global weakness for the group's top branded product Benicar/Olmetec (olmesartan) in the first quarter.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.